rhIGF-1 (CEP-151) Phase II Pilot Study Assesses Tolerability and Effect on Brain Lesions in Multiple Sclerosis

Multiple Sclerosis (MS) is a debilitating neurodegenerative disease characterized by demyelination and progressive neurological disability. A major contributor to this progression is the failure of oligodendrocyte progenitor cells (OPCs) to differentiate into myelinating oligodendrocytes, a gap not fully addressed by current immunomodulatory therapies. Preclinical research highlights rhIGF-1 (recombinant human Insulin-Like Growth Factor-1) as crucial for oligodendrocyte differentiation, survival, and myelin integrity. In animal models of MS (EAE), exogenous rhIGF-1 administration effectively closes the disrupted BBB, reduces the number and severity of demyelinating lesions, and improves neurological function, providing a strong rationale for its investigation in human MS.

This was a 48-week (24-week baseline followed by a 24-week treatment) Phase II pilot study designed to assess the tolerability, safety, and effect of rhIGF-1 (CEP-151) on brain MRI lesions in patients with MS. All subjects enrolled in the study received rhIGF-1 (CEP-151) via subcutaneous injection twice a day (BID). For subjects who had previously participated in study MS301, their starting dose in this trial (MS306) was based on their dose at the completion of MS301. The study aimed to translate the promising preclinical neuroprotective and remyelinating effects of rhIGF-1 into a clinical setting.

The provided abstract snippet details the rationale and study design for this Phase II pilot study but does not present any specific results or findings from the trial. Therefore, no quantitative data regarding the tolerability, safety, or effect of rhIGF-1 (CEP-151) on brain MRI lesions in MS patients can be reported at this time. The study's primary objective was to examine efficacy and safety, tolerability, and the effect of CEP-151 on brain MRI lesions in patients with MS, but the outcomes are not included in this abstract.